- Home
- ERAS vs GGAL Comparison
ERAS vs GGAL Comparison
Compare ERAS & GGAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ERAS | GGAL |
|---|---|---|
| Founded | 2018 | 1905 |
| Country | United States | Argentina |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 7.0B |
| IPO Year | 2021 | 2001 |
Fundamental Metrics
Financial Performance| Metric | ERAS | GGAL |
|---|---|---|
| Price | $14.34 | $37.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | $14.25 | ★ $69.00 |
| AVG Volume (30 Days) | ★ 4.1M | 647.1K |
| Earning Date | 05-08-2026 | 03-07-2023 |
| Dividend Yield | N/A | ★ 3.70% |
| EPS Growth | ★ 36.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $62.29 |
| Revenue Next Year | N/A | $22.88 |
| P/E Ratio | ★ N/A | $13.36 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.11 | $26.06 |
| 52 Week High | $24.28 | $62.11 |
Technical Indicators
Market Signals| Indicator | ERAS | GGAL |
|---|---|---|
| Relative Strength Index (RSI) | 33.45 | 22.31 |
| Support Level | $14.00 | N/A |
| Resistance Level | $15.03 | $45.33 |
| Average True Range (ATR) | 1.00 | 1.41 |
| MACD | -0.11 | -0.50 |
| Stochastic Oscillator | 14.27 | 3.38 |
Price Performance
Historical ComparisonAbout ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
About GGAL Grupo Financiero Galicia S.A.
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. The company generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.